1- Maxillofacial Surgery Service, Hospital Juárez de México, Mexico City, Mexico. 2- Research División, Hospital Juárez de México, Mexico City, Mexico. 3- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (FES-Iztacala UNAM), Estado de México, México. 4- Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México. 5- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (FES-Iztacala UNAM), Estado de México, México. , marioadan@inmunoquimica.com
Abstract: (3996 Views)
Central ossifying fibroma is a benign, slow-growing tumor of mesenchymal origin with a predilection for the mandibular premolar and molar areas. The immunophenotype of T cells involved in the antitumor response against this benign tumor is unknown. In this case report, we described a case of a 48-year-old woman presenting with a very large recurrent ossifying fibroma in the mandible, which was successfully treated with hemimaxillectomy. In addition, we evaluated the expression of programmed cell death 1 receptor (PD-1), lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), CD69 (activation inducer molecule) and CD25 (α chain of the high-affinity IL-2 receptor) in T cell populations from the tumor and peripheral blood of this uncommon lesion. The patient presented recurrent ossifying fibroma, and the tumor-infiltrating and peripheral blood T cells showed expression of PD-1, LAG-3, and TIM-3, suggesting an exhausted T cell response.
García-Muñoz A, Nieto-Velázquez N G, Damian-Morales G, Liceaga-Escalera C, Montoya-Perez L A, Cruz-Vélez M, et al . PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report. Int J Mol Cell Med 2020; 9 (4) :307-311 URL: http://ijmcmed.org/article-1-1403-en.html